Abstract
Melanoma is the most aggressive form of skin cancer and advanced stages are inevitably resistant to conventional therapeutic agents. In particular, epigenetic strategies might open interesting new perspectives in combination with conventional ones. Current therapeutic strategies, in particular for metastatic melanoma, do not give great results in terms of survival. Herein, I review HDACis and microRNAs for melanoma. A critical discussion of all the recent findings on this topic is also included. In my view, further studies are needed to understand the toxicity of these treatments in order to improve survival of melanoma patients.
Keywords: Melanoma, Epigenetic, microRNAs, CHEMOTHERAPIC AGENTS, nucleosomes, HDAC Inhibitor, acetylation, methylation, phosphorylation, ubiquitination
Anti-Cancer Agents in Medicinal Chemistry
Title: Melanoma and Epigenetic Treatment: Past and Future
Volume: 12 Issue: 3
Author(s): Caterina AM La Porta
Affiliation:
Keywords: Melanoma, Epigenetic, microRNAs, CHEMOTHERAPIC AGENTS, nucleosomes, HDAC Inhibitor, acetylation, methylation, phosphorylation, ubiquitination
Abstract: Melanoma is the most aggressive form of skin cancer and advanced stages are inevitably resistant to conventional therapeutic agents. In particular, epigenetic strategies might open interesting new perspectives in combination with conventional ones. Current therapeutic strategies, in particular for metastatic melanoma, do not give great results in terms of survival. Herein, I review HDACis and microRNAs for melanoma. A critical discussion of all the recent findings on this topic is also included. In my view, further studies are needed to understand the toxicity of these treatments in order to improve survival of melanoma patients.
Export Options
About this article
Cite this article as:
AM La Porta Caterina, Melanoma and Epigenetic Treatment: Past and Future, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (3) . https://dx.doi.org/10.2174/187152012800228760
DOI https://dx.doi.org/10.2174/187152012800228760 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Branched-Chain Amino Acids and Pigment Epithelium-Derived Factor: Novel Therapeutic Agents for Hepatitis C Virus-Associated Insulin Resistance
Current Medicinal Chemistry Biomarker Diversity, Validation and Clinical Translation: Tenets for Emergent Personalized Medicine Initiatives
Current Pharmacogenomics and Personalized Medicine An Update on NLRP3 Inflammasome Activation by Engineered Nanomaterials
Current Bionanotechnology (Discontinued) Predicting Hub Genes of Glioblastomas Based on a Support Vector Machine Combined with CFS Algorithms
Current Bioinformatics Berberine as a Promising Safe Anti-Cancer Agent- Is there a Role for Mitochondria?
Current Drug Targets Distamycins: Strategies for Possible Enhancement of Activity and Specificity
Mini-Reviews in Medicinal Chemistry Anti-Cancer Cytotoxic Effects of Multiwalled Carbon Nanotubes
Current Pharmaceutical Design Financial Returns on R&D: Looking Back at History, Looking Forward to Adaptive Licensing
Reviews on Recent Clinical Trials Immunomodulatory Activity of Garlic
Current Immunology Reviews (Discontinued) STAT 3 as a Target for Cancer Drug Discovery
Current Medicinal Chemistry Nanoparticles Mediated Target-specific Drug Delivery in Prostate Cancer: An In-depth Review
Current Medicinal Chemistry Curcumin and its Formulations: Potential Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Breast Cancer and Flavonoids - A Role in Prevention
Current Pharmaceutical Design Genetic Variation at the Human MGMT Locus and its Biological Consequences
Current Pharmacogenomics Galectin-1 as a Potential Therapeutic Agent for Amyotrophic Lateral Sclerosis
Current Drug Targets Combinatorial Nanoparticles for Cancer Diagnosis and Therapy
Current Medicinal Chemistry Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies
Anti-Cancer Agents in Medicinal Chemistry Commercial Opportunities and Ethical Pitfalls in Personalized Medicine: A Myriad of Reasons to Revisit the Myriad Genetics Saga
Current Pharmacogenomics and Personalized Medicine Molecular Mechanisms of Tumor Invasion and Metastasis: An Integrated View
Current Molecular Medicine